Prospective multicenter study of the impact of the 21-gene recurrence score (RS) assay on medical oncologist (MO) and patient (pt) adjuvant breast cancer (BC) treatment selection

被引：0
|
作者：
Lo, S. S.
Norton, J.
Mumby, P. B.
Smerage, J.
Kash, J.
Chew, H. K.
Hayes, D.
Epstein, A.
Albain, K. S.
机构：
[1] Loyola Univ, Maywood, IL 60153 USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
[3] Edward Hosp, Naperville, IL USA
[4] Univ Calif Davis, Sacramento, CA 95817 USA
[5] Mt Sinai Med Ctr, New York, NY 10029 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
577
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Decision Impact and Economic Evaluation of the 21-gene Recurrence Score (RS) Assay for Physicians and Patients in Japan
    Yamauchi, H.
    Nakagawa, C.
    Yamashige, S.
    Takei, H.
    Yagata, H.
    Yoshida, A.
    Chien, R.
    Hornberger, J.
    Nakamura, S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S378 - S378
  • [42] The 21-Gene Recurrence Score (RS) in Special Histologic Subtypes of Breast Cancer: A Population-Based Study
    Gulbahce, H. Evin
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 105 - 106
  • [43] The 21-Gene Recurrence Score (RS) in Special Histologic Subtypes of Breast Cancer: A Population-Based Study
    Gulbahce, H. Evin
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 105 - 106
  • [44] A summary of head-to-head comparisons of patient (pt) risk classifications by the 21-gene Recurrence Score® (RS) assay and other genomic assays for early breast cancer (EBC)
    Varga, Z.
    McCullough, D.
    Lau, A.
    Stoppler, M.
    Baehner, F. L.
    Seidman, A. D.
    BREAST, 2017, 32 : S98 - S98
  • [45] Summary of head-to-head comparisons of patient (pt) risk classifications by the 21-gene recurrence score (RS) assay and other genomic assays for early breast cancer (EBC)
    Varga, Z.
    Sinn, P.
    McCullough, D.
    Lau, A.
    Stoppler, M. C.
    Baehner, F. L.
    Chao, C.
    Seidman, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [46] 21-gene recurrence score and adjuvant chemotherapy decisions in patients with invasive lobular breast cancer
    Chen, Xiang-Hong
    Zhang, Wen-Wen
    Wang, Jun
    Sun, Jia-Yuan
    Li, Feng-Yan
    He, Zhen-Yu
    Wu, San-Gang
    BIOMARKERS IN MEDICINE, 2019, 13 (02) : 83 - 93
  • [47] Impact of a 21-Gene Recurrence Score Test on the Choice of Adjuvant Chemotherapy for Hormone Receptor-positive Early-stage Breast Cancer: A Prospective Study
    Zeng, Yinduo
    Li, Qian
    Qin, Tao
    Li, Shunrong
    Jin, Liang
    Wu, Jiannan
    Chen, Kai
    Deng, Heran
    Rao, Nanyan
    Liu, Qiang
    Su, Fengxi
    Jia, Weijuan
    Yao, Herui
    ANTICANCER RESEARCH, 2017, 37 (08) : 4539 - 4547
  • [48] Outcome disparities by age and 21-gene recurrence score® (RS) result in hormone receptor positive (HR plus ) breast cancer (BC)
    Shak, S.
    Miller, D. P.
    Howlader, N.
    Gliner, N.
    Howe, W.
    Schussler, N.
    Cronin, K.
    Baehner, F. L.
    Penberthy, L.
    Petkov, V. I.
    ANNALS OF ONCOLOGY, 2016, 27
  • [49] The 21-gene Recurrence Score: Impact on Adjuvant Chemotherapy Decisions in Early Breast Cancer, West of Scotland Cancer Centre Experience
    Morton, A.
    MacPherson, I.
    Marashi, H.
    CLINICAL ONCOLOGY, 2017, 29 (06) : E101 - E101
  • [50] Impact of the 21-gene Recurrence Score assay on the adjuvant treatment of breast cancer patients with 1-3 positive lymph nodes in an academic centre in Ontario.
    Torres, Sofia
    Trudeau, Maureen E.
    Gandhi, Sonal
    Warner, Ellen
    Verma, Sunil
    Pritchard, Kathleen I.
    Petrella, Teresa M.
    Hew-Shue, Mark
    Chao, Calvin
    Eisen, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345